Evidence map›Paper›PMID 36207284›Full record

ArticleAdvanced materials (Deerfield Beach, Fla.)2022

Immune Profiling and Multiplexed Label-Free Detection of 2D MXenes by Mass Cytometry and High-Dimensional Imaging.

Laura Fusco, Arianna Gazzi, Christopher E Shuck, Marco Orecchioni, Dafne Alberti, Sènan Mickael D'Almeida, Darawan Rinchai, Eiman Ahmed, Ofer Elhanani, Martina Rauner and 8 more

Open access · hybridAbstract read
In one paragraph

Article in Advanced materials (Deerfield Beach, Fla.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 35 citations in OpenAlex.

  1. Label-free NbNanoscale horizons · 2026
    Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 8 institutions in 6 countries.

Laura FuscoImmuneNano Laboratory, Department of Biomedical Sciences, University of Padua, Padua, 35129, Italy.ORCID https://orcid.org/0000-0003-1418-507X
Arianna GazziImmuneNano Laboratory, Department of Biomedical Sciences, University of Padua, Padua, 35129, Italy.ORCID https://orcid.org/0000-0002-4142-485X
Christopher E ShuckA. J. Drexel Nanomaterials Institute and Department of Materials Science and Engineering, Drexel University, Philadelphia, PA, 19104, USA.
Marco OrecchioniLa Jolla Institute for Immunology, San Diego, CA, 92037, USA.
Dafne AlbertiLaboratory of Synthetic Immunology, Oncology and Immunology Section, Department of Surgery Oncology and Gastroenterology, University of Padua, Padua, 35124, Italy.
Sènan Mickael D'AlmeidaFlow Cytometry Core Facility, School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, 1015, Switzerland.
Darawan RinchaiHuman Immunology Division, Translational Medicine Department, Sidra Medicine, Doha, 26999, Qatar.
Eiman AhmedHuman Immunology Division, Translational Medicine Department, Sidra Medicine, Doha, 26999, Qatar.
Ofer ElhananiDepartment of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, 7610001, Israel.
Martina RaunerDepartment of Medicine III, Center for Healthy Aging, Technical University Dresden, 01307, Dresden, Germany.
Barbara ZavanDepartment of Medical Sciences, University of Ferrara, Ferrara, 44121, Italy.
Jean-Charles GrivelDeep Phenotyping Core, Sidra Medicine, Doha, 26999, Qatar.
Leeat KerenDepartment of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, 7610001, Israel.
Giulia PasqualLaboratory of Synthetic Immunology, Oncology and Immunology Section, Department of Surgery Oncology and Gastroenterology, University of Padua, Padua, 35124, Italy.
Davide BedognettiHuman Immunology Division, Translational Medicine Department, Sidra Medicine, Doha, 26999, Qatar.
Klaus LeyLa Jolla Institute for Immunology, San Diego, CA, 92037, USA.
Yury GogotsiA. J. Drexel Nanomaterials Institute and Department of Materials Science and Engineering, Drexel University, Philadelphia, PA, 19104, USA.
Lucia Gemma DeloguImmuneNano Laboratory, Department of Biomedical Sciences, University of Padua, Padua, 35129, Italy.ORCID https://orcid.org/0000-0002-2329-7260
Qatar Airways (Qatar) · QAUniversity of Padua · ITDrexel University · USLa Jolla Institute for Immunology · USWeizmann Institute of Science · ILÉcole Polytechnique Fédérale de Lausanne · CHTechnische Universität Dresden · DEUniversity of Ferrara · IT

Funding

Vascular macrophages and T cells in atherosclerosisR35HL145241 · NHLBI · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI LEY, KLAUS F. · 2019 to 2025
$5.9M
Center for New ScientistsEnoch Foundation Research FundEuropean Research Council 94811European Union's Horizon 2020 Research and Innovation Programme 101029140European Union's Horizon 2020 Research and Innovation Programme 734381Israeli Council for Higher EducationIsrael Precision Medicine PartnershipIsrael Science Foundation 2481/20Israel Science Foundation 3830/21National Science Foundation DMR-2035007NHLBI NIH HHS R35 HL145241Schwartz/Reisman Collaborative Science ProgramSidra Medicine Internal Funds SDR400025Weizmann Data Science Research CenterWeizmann Institute of Science
6 · The paper itself

Abstract

There is a critical unmet need to detect and image 2D materials within single cells and tissues while surveying a high degree of information from single cells. Here, a versatile multiplexed label-free single-cell detection strategy is proposed based on single-cell mass cytometry by time-of-flight (CyTOF) and ion-beam imaging by time-of-flight (MIBI-TOF). This strategy, "Label-free sINgle-cell tracKing of 2D matErials by mass cytometry and MIBI-TOF Design" (LINKED), enables nanomaterial detection and simultaneous measurement of multiple cell and tissue features. As a proof of concept, a set of 2D materials, transition metal carbides, nitrides, and carbonitrides (MXenes), is selected to ensure mass detection within the cytometry range while avoiding overlap with more than 70 currently available tags, each able to survey multiple biological parameters. First, their detection and quantification in 15 primary human immune cell subpopulations are demonstrated. Together with the detection, mass cytometry is used to capture several biological aspects of MXenes, such as their biocompatibility and cytokine production after their uptake. Through enzymatic labeling, MXenes' mediation of cell-cell interactions is simultaneously evaluated. In vivo biodistribution experiments using a mixture of MXenes in mice confirm the versatility of the detection strategy and reveal MXene accumulation in the liver, blood, spleen, lungs, and relative immune cell subtypes. Finally, MIBI-TOF is applied to detect MXenes in different organs revealing their spatial distribution. The label-free detection of 2D materials by mass cytometry at the single-cell level, on multiple cell subpopulations and in multiple organs simultaneously, will enable exciting new opportunities in biomedicine.

Indexed as

NanostructuresTransition ElementsAnimalsHumansMiceTissue DistributionTransition Elementsbiocompatibilitybiomedical applicationsimmune systemMXenesnanomedicine

Identifiers

PMID36207284
PMCPMC10915970
OpenAlexW4303574980

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.